


Response to Brosch et al.

Jussi Pihlajamäki, Carles Lerin, Dorota Kaminska, Sari Venesmaa, Paula Itkonen, Tanner Boes, Thomas Floss, Joshua Schroeder, Farrell Dearie, Sarah Crunkhorn, Furkan Burak, Josep C. Jimenez-Chillaron, Tiina Kuulasmaa, Pekka Miettinen, Peter J. Park, Imad Nasser, Zhenwen Zhao, Zhaiyi Zhang, Yan Xu, Wolfgang Wurst, Hongmei Ren, Andrew J. Morris, Stefan Stamm, Allison B. Goldfine, Markku Laakso, and Mary Elizabeth Patti

Figure S1. Response Figure



(A) Microarray gene expression from lean and obese human liver biopsy samples for 2 of 3 SFRS10 probes (Affymetrix U133A).  
 (B) Schematic figure of exon structure for SFRS10 isoforms, demonstrating primer locations for PCR strategies employed by Patti lab and Brosch groups.  
 (C) Expression of SFRS10 isoforms Tra2b1 and Tra2b4 in liver (left) and muscle (right) from wild-type (WT, white bars) and SFRS10 heterozygous mice (Het, black bars), as determined by quantitative RT-PCR. Values are expressed relative to wild-type (assigned a mean value of 1).  
 (D) Expression of total SFRS10 (left) and Tra2b4 (right) in Hepa1c cells treated with scrambled control or SFRS10 shRNA.  
 (E) Correlation of Tra2b1 (expressed as proportion of [Tra2b1 + Tra2b4]) with BMI (Spearman correlation  $r = -0.249$ ,  $p = 0.035$ ).  
 For all panels, \* indicates  $p < 0.05$ , and error bars represent SEM.